Stereotaxis’ (STXS) “Buy” Rating Reiterated at Roth Capital

Roth Capital reissued their buy rating on shares of Stereotaxis (NYSEAMERICAN:STXS) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a $4.00 target price on the stock. Roth Capital also issued estimates for Stereotaxis’ Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.23) EPS.

Separately, UBS Group set a $4.00 price target on Stereotaxis in a report on Wednesday. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Stereotaxis presently has a consensus rating of “Buy” and a consensus price target of $4.00.

Stereotaxis Price Performance

NYSEAMERICAN:STXS opened at $2.72 on Wednesday. The stock has a market capitalization of $247.71 million, a PE ratio of -9.38 and a beta of 1.65. The business’s 50-day simple moving average is $2.96 and its 200-day simple moving average is $2.51. Stereotaxis has a fifty-two week low of $1.54 and a fifty-two week high of $3.59.

Institutional Investors Weigh In On Stereotaxis

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in Stereotaxis by 4.2% in the third quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock worth $10,702,000 after purchasing an additional 138,482 shares in the last quarter. Essex Investment Management Co. LLC grew its position in shares of Stereotaxis by 3.5% during the 3rd quarter. Essex Investment Management Co. LLC now owns 1,598,114 shares of the company’s stock worth $4,970,000 after buying an additional 53,358 shares during the period. Envestnet Asset Management Inc. bought a new stake in shares of Stereotaxis in the 3rd quarter valued at $413,000. Cherry Creek Investment Advisors Inc. lifted its position in shares of Stereotaxis by 52.4% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 54,665 shares of the company’s stock valued at $170,000 after acquiring an additional 18,799 shares during the period. Finally, Jane Street Group LLC bought a new position in Stereotaxis during the second quarter worth $78,000. Institutional investors and hedge funds own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.